O
1.49
0.05 (3.47%)
| Previous Close | 1.44 |
| Open | 1.48 |
| Volume | 11,310 |
| Avg. Volume (3M) | 68,292 |
| Market Cap | 78,194,496 |
| Price / Book | 7.94 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2024 |
| Diluted EPS (TTM) | -0.380 |
| Current Ratio (MRQ) | 0.280 |
| Operating Cash Flow (TTM) | -2.94 M |
| Levered Free Cash Flow (TTM) | -3.09 M |
| Return on Assets (TTM) | -291.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | OKYO Pharma Limited | Mixed | Mixed |
AIStockmoo Score
-0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| Macro Environment | 0.0 |
| AI Insight | NA |
| Weighted Average | -0.28 |
Select this tab to load the latest available analysis.
|
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 34.41% |
| % Held by Institutions | 6.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Maven Securities Ltd | 30 Jun 2026 | 809,317 |
| Choreo, Llc | 30 Jun 2026 | 33,255 |
| Efg International Ag | 30 Jun 2026 | 923 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |